Dividend criteria checks 0/6
Novavax does not have a record of paying a dividend.
|Industry average yield||2.9%|
|Next dividend pay date||n/a|
|Ex dividend date||n/a|
|Dividend per share||US$0|
|Earnings per share||-US$13.39|
|Dividend yield forecast in 3Y||0%|
Recent dividend updates
Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) OutlookMar 05
COVID-19 remains global health emergency - WHOOct 19
Novavax spikes ahead of presentations on COVID-19 vaccine portfolioOct 10
US Supreme Court declines to hear challenge of COVID vaccine mandate for health workersOct 03
Novavax makes 1M doses of its COVID-19 vaccine available for use in the UKSep 27
EU clears Novavax's COVID-19 shot for use as a booster dose in adultsSep 12
Novavax wins EU backing for COVID-19 booster shotSep 01
Novavax: Finding Its NicheAug 23
Novavax COVID vaccine gets provisional approval in New Zealand as booster shotAug 17
Novavax Q2: Time To Turn Bullish After The Massive CollapseAug 11
Bearish: Analysts Just Cut Their Novavax, Inc. (NASDAQ:NVAX) Revenue and EPS estimatesAug 11
Novavax COVID-19 shot is linked to rare cases of heart inflammation – EU agencyAug 03
Novavax gets Japanese regulatory nod for use of its COVID vaccine in teensJul 26
Serum Institute of India supplies Novavax's COVID vaccine in USJul 18
Novavax to deliver 3.2M doses of COVID-19 vaccine to U.S.Jul 11
Novavax wins EU nod to use COVID-19 vaccine in adolescentsJul 05
Taiwan to get 504K doses of Novavax COVID vaccine in 1st lot this weekJun 29
Novavax seeks label expansion for COVID-19 shot in CanadaJun 23
The Novavax Vaccine, FinallyJun 08
Is Novavax (NASDAQ:NVAX) Using Debt In A Risky Way?May 24
Novavax: Buying Here Will Not End WellMay 18
Novavax: Don't Catch The Falling KnivesMay 07
Novavax: Management's Revenue Guidance - If It Can Be Trusted - Makes The Bull CaseApr 21
Stability and Growth of Payments
|Month||Dividend Per Share (annual)||Avg. Yield (%)|
Stable Dividend: Insufficient data to determine if NVAX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NVAX's dividend payments have been increasing.
Dividend Yield vs Market
|Novavax Dividend Yield vs Market|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||5.2%|
|Industry Average (Biotechs)||2.9%|
|Analyst forecast in 3 Years (NVAX)||0%|
Notable Dividend: Unable to evaluate NVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NVAX has not reported any payouts.